Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective for the company in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Up 1,311.2 %

Brainstorm Cell Therapeutics stock opened at $3.25 on Tuesday. Brainstorm Cell Therapeutics has a 1-year low of $2.01 and a 1-year high of $11.89. The company has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.43. The company has a market cap of $227.76 million, a P/E ratio of -10.16 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). During the same period in the prior year, the firm posted ($0.27) earnings per share. On average, equities research analysts forecast that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.